ONKO BCG ® 100
Oncological immunotherapy (likely bladder cancer)
ApprovedCommercial
Key Facts
Indication
Oncological immunotherapy (likely bladder cancer)
Phase
Approved
Status
Commercial
Company
About Synthaverse
Synthaverse is a modern, dynamically developing Polish biotech that leverages its expertise and proprietary technologies to develop and deliver solutions shaping global health. The company has a diversified portfolio of commercial and development-stage products, primarily in immunotherapy, and supports its innovation through close cooperation with scientific centers. Its ambition is to push the boundaries of medicine while maintaining a strong focus on contract manufacturing and laboratory reagents. Led by CEO Mieczysław Starkowicz, the company combines decades of experience with a forward-looking approach to research and production.
View full company profileTherapeutic Areas
Other Oncological immunotherapy (likely bladder cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| ONKO BCG ® 50 | Synthaverse | Approved |